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Background and Aims: Neurological soft signs (NSS) are more common in schizophrenic 
psychoses and in genetically high-risk individuals than in healthy controls. But nothing is 
known so far regarding individuals with a clinical at-risk mental state (ARMS). The goals of 
our study therefore were a) to compare the NSS frequency in ARMS individuals to that of 
first-episode psychosis (FEP) patients; and b) to test whether NSS could predict the transition 
to psychosis.  
Methods: Neurological soft signs were assessed using a shortened version of the 
Neurological Evaluation Scale (NES). Fifty-three ARMS individuals (16 with later transition to 
psychosis = ARMS-T, and 37 without transition = ARMS-NT) and 27 FEP patients were 
recruited through the Basel Early Detection Clinic FePsy.  
Results: Of the FEP patients 37% showed NSS. We found no significant differences between 
FEP and ARMS-T patients or between ARMS-NT and ARMS-T. 
Conclusions: Our findings of NSS being present already before transition to psychosis to the 
same extent as after transition provide further support to the neurodevelopmental 
hypothesis of schizophrenic psychoses. Furthermore, our findings might indicate that ARMS-
NT individuals also suffer from some sort of neurodevelopmental abnormalities. 
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Neurological soft signs (NSS) are minor abnormalities in sensory integration, motor 
coordination, and sequencing of complex motor acts often manifesting themselves in 
patients with schizophrenia or schizophrenia-spectrum disorders (Heinrichs and Buchanan, 
1988). They have also been reported in other neuropsychiatric disorders, such as chronic 
posttraumatic stress disorder (Gurvits et al., 2000), bipolar disorder (Negash et al., 2004), 
obsessive compulsive disorder (Mergl and Hegerl, 2005) as well as in patients suffering from 
neurodegenerative diseases (Chan et al., 2011). However, their prevalence has been shown 
to be higher in schizophrenia than in other psychiatric disorders (Cox and Ludwig, 1979; 
Jaafari et al., 2011).  
In the last two decades, NSS have been studied in patients with chronic schizophrenia (King 
et al., 1991), first-episode schizophrenia (FEP) (Dazzan and Murray, 2002; Peralta et al., 
2011) and in individuals with a high genetic risk for schizophrenia (Lawrie et al., 2001). 
Evidence suggests that NSS are more common in chronic schizophrenia and FEP patients 
than in healthy controls (King et al., 1991; Rossi et al., 1990). In the largest study to date, 
78% of first episode antipsychotic-naïve patients showed at least one neurological 
abnormality (Peralta et al., 2011). NSS were also found to be more frequent in nonpsychotic 
genetically high-risk individuals with at least two first- and/or second-degree relatives with 
schizophrenia than in healthy controls (Gourion et al., 2004; Lawrie et al., 2001). 
Furthermore, in groups of normal volunteers, individuals presenting higher schizotypy 
showed significantly more soft signs as expressed by higher “Neurological Evaluation Scale” 
(NES) total scores and higher "Sequencing of Complex Motor Acts” and “Other Soft Signs” 
subscale scores (Barkus et al., 2006; Mechri et al., 2010; Theleritis et al., 2012).  
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Neuroanatomical correlates of NSS were extensively investigated in healthy individuals. They 
seem to be associated with decreased volume of the inferior frontal gyrus, middle and 
superior temporal gyrus, and anterior cingulate gyrus (Dazzan et al., 2006). In FEP patients, 
an excess of NSS has been found to be associated with reduced brain volume in subcortical 
(basal ganglia, thalamus and cerebellum) and frontal cortical areas (premotor area, frontal 
gyrus), independent of antipsychotic medication (Dazzan et al., 2004; Janssen et al., 2009; 
Thomann et al., 2009). These regions, known to play a key role in sensory and motor 
integration may thus represent the neuroanatomical substrate of NSS, at least in psychotic 
patients. The fact that NSS in non-psychotic and psychotic individuals have partially different 
anatomical correlates may indicate that different pathogenic mechanisms are responsible 
for the presence of NSS in different populations (Thomann et al., 2009).  
 
It has been hypothesized that early damages of the central nervous system (CNS) and 
neurodevelopmental abnormalities could lead to an increased expression of NSS (Peralta et 
al., 2011). At the same time, schizophrenic psychoses are regarded as arising partly from 
neurodevelopmental problems. So there might be a shared common etiology of NSS and 
schizophrenic psychoses. As an indication of that, delayed speech or walking in childhood 
are important risk factors not only for neurological soft signs (Peralta et al., 2011), but also 
for schizophrenic psychoses (Welham et al., 2009). Moreover, some studies found a 
relationship between a history of obstetric complications and neurological soft signs (Bersani 
et al., 2012; Peralta et al., 2006) in schizophrenia patients. However, this relationship 
remains controversial as some found a negative relationship in schizophrenia (Mrad et al., 
2010) or first-episode psychosis (Boks et al., 2007).  
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Thus, although the etiology of NSS remains unclear (Chan et al., 2010), the high prevalence 
of NSS in patients suffering from schizophrenic psychoses as well as their association with 
obstetric complications and neurodevelopmental delay have led to the assumption that 
these neurological abnormalities are an expression of underlying neurodevelopmental 
disturbances (Leask et al., 2002; Peralta et al., 2011). 
 
Growing evidence proposes that NSS tend to be stable over time, irrespective of whether 
psychopathological symptoms are observable (Chan et al., 2010; Neelam et al., 2011). Due to 
their association to the illness, their presence irrespective of the disease state, and their 
familial association, NSS have been proposed as possible endophenotypes for schizophrenia 
(i.e. trait-markers that are present independent of the manifestation of the disease) (Chan 
and Gottesman, 2008; Neelam et al., 2011).  
Although some authors have suggested NSS as potential trait-marker for psychosis 
proneness (Barkus et al., 2006), to our knowledge no study has yet examined NSS in a group 
of clinical At-Risk Mental State individuals (ARMS), i.e. individuals with clinical symptoms of a 
putative prodromal state of psychosis. Hence, the main goal of this study was to compare 
the NSS frequency in ARMS individuals who later in fact made the transition to psychosis 
(ARMS-T) to that of a group of FEP. Supporting a neurodevelopmental model of NSS, we 
expected to observe no difference between these two groups. Our secondary goal was to 
test whether NSS predict the transition to psychosis by comparing individuals at-risk who 
made the transition to psychosis and those who did not (ARMS-T vs. ARMS-NT).  Because 
NSS have been reported to be more prevalent in patients with schizophrenia compared to 
other psychiatric disorders and non-psychiatric controls (Cox and Ludwig, 1979; Jaafari et al., 
2011), we hypothesized that NSS would be more severe in ARMS-T than in ARMS-NT.  






All data analyzed in this study were collected within the prospective Früherkennung 
von Psychosen (FePsy) study, which aims to improve the early detection of psychosis. A 
more detailed description of the overall study design can be found elsewhere (Riecher-Rössler et al., 
2007; Riecher-Rössler et al., 2009). All participants were recruited between March 2000 and 
November 2003 via the FePsy-Clinic at the Psychiatric Outpatient Department of the 
University Hospital Basel, which was set up specifically to identify, assess, and treat 
individuals in the very early stages of developing psychosis. The study was approved by the 
ethics committee of the University of Basel and all participants provided written informed 
consent. 
Screening was performed with the Basel Screening Instrument for Psychosis (BSIP) 
(Riecher-Rössler et al., 2008), which is based on the DSM-III-R prodromal symptoms 
(American Psychiatric Association, 1987) and other early signs and risk factors, such as social 
decline, drug abuse, previous psychiatric treatment or genetic risk. It also incorporates four 
psychosis items of the expanded version of the Brief Psychiatric Rating Scale (BPRS) (Lukoff 
et al., 1986; Ventura et al., 1993) for assessing (pre-) psychotic phenomena. Individuals were 
classified by the BSIP as being in an At-Risk Mental State (ARMS) for psychosis, having a first 
episode psychosis (FEP), or not being at risk for psychosis (usually having other psychiatric 
disorders). 
ARMS individuals met one of the following inclusion criteria: i) psychotic symptoms 
below the transition cut-off (“attenuated” psychotic symptoms) during the past year; ii) 
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psychotic symptoms above the transition cut-off, but not lasting more than a week and 
resolving spontaneously; iii) first or second degree relative with psychotic disorder and at 
least two further risk factors according to the screening instrument (not necessarily including 
the presence of pre-psychotic symptoms); and iv) unspecific risk factors and indicators, such 
as prodromal symptoms and marked social decline. These criteria are in close 
correspondence to those of the PACE clinic (Yung et al., 2007) and have been shown to have 
a good inter-rater reliability and a high predictive validity (Riecher-Rössler et al., 2008). 
FEP individuals met the transition criteria to psychosis according to Yung et al. (1998) 
corresponding to at least one of the following symptoms at least several times a week during 
more than 1 week:  i) suspiciousness (Brief Psychiatric Rating Scale (BPRS) > 5); ii) unusual 
thought content (BPRS >5); iii) hallucinations (BPRS >4); iv) conceptual disorganization (BPRS 
>5) (Lukoff et al., 1986; Ventura et al., 1993). 
Exclusion criteria for both ARMS and FEP individuals were age younger than 18 years, 
insufficient knowledge of German, IQ <70, previous episode of a schizophrenic psychosis, 
psychosis clearly due to organic reasons or substance abuse, and psychotic symptoms within 
a clearly diagnosed depression or borderline personality disorder. 
All ARMS and FEP individuals included in the FePsy study underwent an extensive 
entry examination. In addition, ARMS individuals were followed-up at regular intervals in 
order to distinguish those who later developed frank psychosis (ARMS-T) from those who did 
not (ARMS-NT). During the first year of the follow-up, ARMS individuals were assessed for 
transition to psychosis monthly, during the second and third years three-monthly, and 
thereafter annually. Transition to psychosis was monitored by applying the transition criteria 
of Yung et al. (1998) described above. 





Neurological soft signs were assessed at study entry using the modified and shortened 
version of the Neurological Evaluation Scale (NES) originally developed by Heinrichs & 
Buchanan (1988). The shortened version of the NES (Sanders et al., 1998) includes only the 
13 items which have been shown to have a sufficient frequency (on each of these items, at 
least 10% of patients have a non-zero rating) and a consistent inter-rater reliability (Sanders 
et al., 2005).  
The NES measures four domains: sensory integration, motor coordination, sequencing of 
complex motor acts, and other soft signs. Each item is rated 0 (no NSS), 1 (mild) or 2 
(severe). The assessment of NSS has been conducted by three psychiatrists trained and 




Psychiatric diagnoses were assessed at study entry using a modified German version of the 
structured clinical interview for DSM-IV disorders (SCID-I) (Wittchen et al., 1997). The 
German version of the SCID-I also allows the transformation of DSM-IV diagnoses into ICD-10 
diagnoses, which we report in this study.  
 
2.4. Assessment	of	psychopathology	
General psychopathology and positive psychotic symptoms were assessed by the expanded 
version of the BPRS (Lukoff et al., 1986; Ventura et al., 1993). The positive symptom scale 
was based on the BPRS items suspiciousness, hallucinations, unusual thought content, and 
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conceptual disorganization. Negative symptoms were assessed by the Scale for the 
Assessment of Negative Symptoms (SANS) (Andreasen, 1989). 
 
2.5. Statistical	methods	
The general analytic approach serves the purpose to give a description of the NSS frequency 
in our three samples (ARMS-NT, ARMS-T and FEP). The SPSS software for Windows (SPSS 
version 19; SPSS, Chicago, Illinois) was used. When the necessary preconditions were met, 
univariate analyses of covariance (ANCOVA) with age and sex as covariates were performed; 
when not, we opted for the non-parametric alternatives Kruskal-Wallis Test (for ordinal 
variables) and Chi-square Test (for dichotomous variables). Because the NSS total score was 
strongly positively skewed we used the log-transformed NSS total score in parametric group 
comparisons (i.e. ANOVAs) To test whether NSS predict the transition to psychosis in ARMS 
individuals, we performed a logistic regression analysis in which transition vs. non-transition 




NSS were assessed in 16 ARMS-T, 37 ARMS-NT, and 27 FEP individuals. Table 1 shows the 
demographic and clinical characteristics of the three patient groups. 44 of the ARMS 
individuals (86.3%) were included due to either attenuated psychotic, brief limited 
intermittent psychotic symptoms or both, one (2%) was included due to genetic risk in 
combination with unspecific risk factors only and six (11.8%) were included due to unspecific 
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risk factors only. There was no statistically significant difference in the frequencies of risk 
groups between ARMS-T and AMRS-NT. All ARMS individuals and 51.8% of the FEP were 
antipsychotic naïve. 
Most individuals with an ARMS also met the criteria for other diagnoses. Table 2 illustrates 
the diagnostic distribution.  
 
--------------------------------------------- Tables 1 and 2 about here----------------------------------------- 
 
The percentage of individuals with at least one NSS was 49% in ARMS-NT, 31% in ARMS-T 
and 37% in FEP. Table 3 illustrates percentages of ARMS-NT, ARMS-T and FEP displaying at 
least one neurological soft sign (mild or severe) for each domain and p-values for differences 
between groups (Kruskal-Wallis-Test). We carried out univariate analyses of covariance with 
group as between-subjects factor, total NSS score (log transformed) as dependent variable 
and sex and age as covariates. The analyses revealed no significant differences in the NSS 
total score neither between ARMS-NT, ARMS-T and FEP (F(2,80)=2.025, p=0.139) nor 
between ARMS-T and FEP analysed alone (F(1,43)=0.685, p=0.413), nor ARMS total group (T 
+ NT) against FEP group (F(1,80)=  0.142, p=0.708), nor when comparing ARMS-T against 
ARMS-NT (F(1, 53)=3.867, p=0.055). Sex (p= 0.233) and age (p=0.125) did not significantly 
differ between groups. 
A logistic regression model that included ARMS-T vs. ARMS-NT as dependent variable and 
the four NES subscales as independent variables revealed that the four NES subscales were 
not predictive for developing psychosis neither alone nor in combination (model likelihood 
ratio test: χ = 6.55, df = 4, p = 0.164).  
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Also when examining the four sub-scores separately using Kruskal-Wallis tests we found no 
significant differences between our three groups: sensory integration (p=0.515), motor 
coordination (p=1.000), sequencing of complex motor acts (p=0.241) and other (p=0.617).  
 
----------------------------------------------- Table 3 about here ---------------------------------------------- 
Mann-Whitney U tests indicated that FEP patients with antipsychotic medication (n = 13) did 
not differ from those without antipsychotic medication (n = 14) with regard to NES total and 
subscale scores. Furthermore, the proportions of FEP patients with at least one NSS were 
highly similar across groups (36% in unmedicated FEP and 38% in medicated FEP). 
Consequently, including antipsychotic medication as a covariate in patient group 
comparisons on NES total and subscale scores did not change the above described results. 
To examine whether neurological soft signs are associated with clinical symptoms, we 
calculated Spearman correlations between NES total score and SANS total, BPRS positive 
symptoms, and BPRS total scores. The results revealed that NES total was not significantly 
correlated with any of these scales, neither in the total group, nor in the ARMS and FEP 
groups (see Table 4). Accordingly, including BPRS total, BPRS positive symptoms and SANS 
total and as covariates in the above described ANCOVA models did not change our results.  
  ----------------------------------------------- Table 4 about here --------------------------------------------- 
 
4. Discussion	
To the best of our knowledge, this is the first assessment of NSS in a group of individuals 
with a clinical risk for developing psychosis. Our first aim was to compare NSS frequency in 
at-risk mental state individuals who later made the transition to psychosis (ARMS-T) to that 
observed in a group of FEP. Since improving the prediction of psychosis is of high clinical 
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relevance (Fusar-Poli et al., 2012), our secondary goal was to test whether NSS predicts the 
transition to psychosis by comparing individuals at-risk who later made the transition to 
psychosis and those who did not (ARMS-T vs. ARMS-NT). Assuming NSS to represent a 
measurable manifestation of neurodevelopmental disruption, we expected i) to find NSS 
already in ARMS-T in about the same frequency as in FEP and ii) to find more NSS in the 
group of at-risk individuals who later made the transition to psychosis than in the group of 
those who did not.  
As expected, the analysis revealed no significant differences between individuals at-risk with 
later transition to psychosis and first episode psychosis patients, i.e. NSS seem to be 
prevalent already before frank transition to psychosis. This finding provides further support 
to the proposed neurodevelopmental model of NSS. That is, minor neurological impairments 
may be  signs of deviant brain development present before the development of frank 
psychosis. They might represent a trait-marker of vulnerability for psychosis (Mayoral et al., 
2012), but potentially also of vulnerability for other neurodevelopmental disorders. The fact 
that we found no significant difference in the frequency of NSS between ARMS who later 
made the transition to psychosis and those who did not, seems to speak for the latter 
interpretation.  Surprisingly, we even observed a trend in the opposite direction (p=0.055), 
with ARMS-NT individuals displaying a slightly higher prevalence rate than ARMS-T. This 
finding not only suggests a low predictive value of NSS for a transition to psychosis, but also 
a low specificity of NSS: in fact, they have been reported not only in schizophrenia but also in 
other psychiatric conditions and are likely to be nonspecific indicators of 
neurodevelopmental abnormalities (Gurvits et al., 2000; Negash et al., 2004). Thus, the high 
prevalence of NSS in our sample of ARMS-NT might also be associated with the psychiatric 
comorbidity in our patients without transition to psychosis or with the at-risk mental state 
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for psychosis itself,which means that these syndromes and disorders might also be 
associated with neurodevelopmental abnormalities. The fact that, in our sample, all 
individuals diagnosed with disorders of development or disorders occurring during childhood 
(F8 and F9) also displayed NSS, provides further support for our hypothesis that NSS may be 
mainly present in patients with a strong neurodevelopmental etiopathogenic mechanism of 
their disorder. On the other hand, as schizophrenic psychoses are most probably an 
etiologically heterogeneous group of disorders, it is likely that some of these patients 
present no or less severe signs of neurodevelopmental abnormalities. 
4.1.	Limitations	
A major limitation of this study is the small group sizes, which does not allow definite 
conclusions. On the other hand, this – to our knowledge – is the first study investigating NSS 
in patients prodromal for psychosis, which are difficult to recruit and to follow up. The 
advantage of our sample is that it was followed for a long period of time (up to 7 years or 
until transition).Therefore, our results are really based on “true” prodromal patients. 
Another limitation of our study is that we did not measure NSS in a matched control group 
of healthy subjects. Thus, we can only assume from the literature that the frequencies of 
NSS detected in our groups are higher than in the general population. 
  
4.2. Conclusions	
To better understand the biological processes behind NSS and their value as biomarker for 
psychosis proneness, additional studies with larger samples of clinical ARMS-T and -NT 
individuals correlating the NSS with other indicators of neurodevelopmental abnormalities 
are necessary. 	
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Table 1: Demographic and clinical characteristics 
 ARMS-NT ARMS-T FEP 
p-value 
 (n=37) (n=16) (n=27) 
Gender:    0.233 
    Women 19 (51.4%) 5 (31.2%) 9 (33.3%)  
    Men 18 (48.6%) 11 (68.8%) 18 (66.7%)  
Age 26.7 (9.95) 27.0 (7.28) 31.2 (8.51) 0.125 
Years of education 10.6 (3.09) 10.8 (2.32) 10.5 (3.12) 0.934 
BPRS total score 39.4 (8.53) 41.2 (9.93) 55.9 (15.1) <0.001 
BPRS Positive symptoms 7.03 (2.39) 8.12 (2.50) 14.0 (3.46) <0.001 
SANS total score 22.6 (17.9) 28.9 (18.5) 33.1 (16.7) 0.062 
Continuous variables are presented as means with standard deviations in parentheses. ARMS-
T = at risk mental state with later transition to psychosis; ARMS-NT = at risk mental state 
without later transition to psychosis; FEP = first episode of psychosis; BPRS = Brief 














(n = 37) 
ARMS-T 
(n = 16) 
ARMS with 
vs. without NSS 
with NSS 
(n = 18) 
n (%) 
without NSS 
(n = 19) 
n (%) 
with NSS 
(n = 5) 
n (%) 
without NSS 
(n = 11) 
n (%) 
Pearson’s  
Chi-Square Test  
F1 3 (17%) 5 (26%) 0 (0%) 2 (20%) p=0.343 
F3 9 (50%) 9 (47%) 2 (40%) 4 (40%) p=0.745 
F4 2 (11%) 4 (21%) 0 (0%) 1 (10%) p=0.396 
F8 and F9 2 (11%) 0 (0%) 1 (20%)  0 (0%) p=0.042 
 
*Diagnoses based on ICD-10 (International Classification of Diseases) in addition to “At Risk Mental State” 
ARMS-T = at risk mental state with later transition to psychosis; ARMS-NT = at risk mental state without later 
transition to psychosis; NSS = neurological soft signs 
 
F1: Mental and behavioural disorders due to psychoactive substance use 
F3: Mood [affective] disorders 
F4: Neurotic, stress-related and somatoform disorders 
F8: Disorders of psychological development 
































28% 6% 22% p=0.241 p=0.344 p=0.344 
Other 
 




49% 31% 37% p=0.429 p=0.957 p=0.755 
ARMS-T = at risk mental state with later transition to psychosis; ARMS-NT = at risk mental state without later 
transition to psychosis; FE = first episode of psychosis; NSS = neurological soft signs 
 
Neurological soft signs (mild or severe) for each domain and overall 
P-values for differences between groups with regard to sum scores (Kruskal-Wallis-Test)  
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Table 4: Spearman correlations between NES total and clinical symptoms 
 
Patient group Scale n 
Correlation 
coefficient (rho) p-value 
Total group BPRS Positive Symptoms 80 -0.09 0.415 
Total group BPRS total 80 -0.12 0.271 
Total group SANS total 80 0.11 0.343 
ARMS BPRS Positive Symptoms 53 -0.11 0.451 
ARMS BPRS total 53 -0.14 0.312 
ARMS SANS total 53 0.16 0.256 
FEP BPRS Positive Symptoms 27 0.05 0.817 
FEP BPRS total 27 -0.10 0.636 
FEP SANS total 27 -0.11 0.577 
 
NES = Neurological Evaluation Scale; ARMS = at risk mental state; FEP = first episode of 
psychosis; BPRS = Brief Psychiatric Rating Scale; SANS = Scale for the Assessment of 
Negative Symptoms 
 
